Clinical Status 2004 PDF Print E-mail
Clinical Status 2004

biocentury.gif

 

 

20. Dezember 2004

Australian Cancer Technology Ltd. (ASX:ACU), Perth, Australia
Bioaccelerate Inc., New York, N.Y.
RESprotect GmbH, Dresden, Germany

  • Product: RP101
  • Business: Cancer
  • Molecular target: NA
  • Description: Inhibits induced chemoresistance and enhances chemosensitivity
  • Indication: Treat metastatic pancreatic cancer
  • Endpoint: NA
  • Status: Started Phase II
  • Milestone: NA
  • The partners began an 8-month, double-blind, placebo-controlled, German Phase II trial in 22 patients with metastatic pancreatic cancer. The patients will receive RP101 tablets in combination with gemcitabine. 
download original PDF document
 
[ Back ]